Metabolism plays a big role in our health, it’s not just about helping your digestive system work smoothly, but the way your body breaks down the food and helps nutrients get absorbed into the body that matters. But often due to one reason or the other, your metabolism can slow down, which then causes issues with people. Many people think that the reason they may be gaining weight could be because of their poor metabolism, so how does one go about fixing this issue and how do you even know that the fault lies with your metabolism.
To understand why your metabolism may be slowing down, we must understand what role it exactly plays. Metabolism is the process your body uses to turn food into energy. It's essential for everything from breathing and digestion to keeping you warm. Several things affect how fast your metabolism works, including your genes, health, and lifestyle. A slow metabolism means your body burns fewer calories, which can lead to tiredness, dry skin, weight gain, and cravings.
There can be many reasons why your metabolism may be slowing down. You inherit some of it, and it tends to slow down as you age, often due to changes in your body and less muscle. Men and women have different metabolisms because of body size, makeup, and hormones. What you eat matters too – not enough healthy food or a very low-calorie or high-fat diet can slow it down. A lazy lifestyle, lack of sleep, and stress can also make your metabolism sluggish. Certain health problems like diabetes or an underactive thyroid, and even environmental factors, may also play a role.
While these are some common signs, it is best to visit a healthcare professional and ask for their opinions before you try a solution. There are many underlying reasons as to why you are experiencing slow metabolism, it can also be a side-effect of some medicine. A healthy lifestyle goes a long way, especially for people who already have digestive issues, kidney or even mental health issues like stress and anxiety.
Feeling tired all the time, even without a good reason, could mean your metabolism is slow. A slow metabolism means your body breaks down food into energy slowly, leaving you with low energy levels. You might feel sluggish or get tired easily throughout the day. Changes in what you eat or your body composition (how much fat and muscle you have) can also make you feel more tired.
Dry skin is common in winter, but if you have it all the time, it could be a sign of a slow metabolism. Thyroid hormones help control your metabolism and also keep your skin hydrated. If your thyroid isn't working right and your metabolism is slow, your skin might get very dry.
If you're eating healthy and exercising but still gaining weight, a slow metabolism could be the problem. A slow metabolism doesn't turn food into energy quickly, so you burn fewer calories. Extra calories are stored as fat, making it hard to lose weight.
Feeling cold even when it's not cold outside can be a sign of a slow metabolism. Your body generates heat through metabolism. If your metabolism is slow, your body temperature might be lower. Some studies show that people with an underactive thyroid or obesity may have lower body temperatures because of a slow metabolism. This can be because of problems with thyroid hormones, which help your body make heat.
Craving sugary or fatty foods can be a sign of a slow metabolism. Studies show that cravings are related to metabolic health. This is especially true for people who don't eat enough healthy foods, have bad eating habits, or have low muscle mass and high fat mass. Cravings might also mean your body isn't getting enough energy from the food you eat, so it wants more energy.
Everyone has mood swings sometimes. But if you have them often, it could be from a slow metabolism. Low energy and hormone problems that come with a slow metabolism can make you irritable and frustrated. Some older research also suggests a link between mental health issues and a slow metabolism.
Digestion and metabolism are connected. Digestion breaks down food, and metabolism turns it into energy. If your metabolism changes, like slowing down, it can affect your digestion. A slow metabolism can cause constipation, bloating, or diarrhea.
Credit: Canva/Eli Lilly
While GLP-1 weight-loss drugs such as Wegovy and Mounjaro have helped patients lose weight, a major concern has been weight regain once the therapy is stopped. Now, a new study by US scientists suggests that a daily pill may help prevent that rebound weight gain.
According to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian, switching to the once-daily orforglipron pill may not only help maintain weight loss but also preserve cardiometabolic benefits.
Orforglipron is US drugmaker Eli Lilly’s first oral pill for weight loss, marketed as Foundayo. In April, it received approval from the US Food and Drug Administration (FDA).
In the Eli Lilly-funded trial, published in the journal Nature Medicine, researchers found that patients in the Phase 3b clinical trial maintained around 75–80 per cent of their weight loss. They also experienced several additional health benefits, including:
The ATTAIN-MAINTAIN trial enrolled patients who had already achieved substantial weight loss that later plateaued while taking weekly injectable GLP-1 drugs during the SURMOUNT-5 trial.
The study randomized:
The results showed that patients switching from tirzepatide to orforglipron maintained an average of 74.7 per cent of their body weight reduction, compared with 49.2 per cent in the placebo group.
Meanwhile, patients who switched from semaglutide to orforglipron maintained 79.3 per cent of their body weight reduction, compared with 37.6 per cent in the placebo arm.
Over the 52-week trial period, participants treated with orforglipron gained:
Eli Lilly licensed orforglipron, the active ingredient in Foundayo, from a Japanese pharmaceutical company in 2018.
Like injectable GLP-1 drugs, Orforglipron is available in six doses ranging from 0.8 mg to 17.2 mg. Patients typically begin at the lowest dose and gradually increase under medical supervision.
Also read: Donald Trump Will Have Fourth Medical Checkup In May, Says White House
Unlike some oral GLP-1 drugs, people taking orforglipron do not need to restrict food or drink intake after taking the pill. Researchers say the small molecule is absorbed quickly into the bloodstream and reaches target tissues efficiently.
Foundayo is not approved for use in children and carries warnings about potential thyroid tumours, including thyroid cancer.
The drugmaker advises patients to watch for symptoms such as:
Credit: iStock/Roche
In a major development for cancer care in India, Swiss pharmaceutical major Roche Pharma has launched Tecentriq SC, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately seven minutes.
While conventional intravenous (IV) infusions can take hours, Tecentriq SC can significantly improve the cancer treatment experience by reducing treatment time by nearly 80 per cent.
The seven-minute injectable immunotherapy has the potential to:
“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.
Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.
First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.
In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases.
According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".
Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi
Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.
The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.
The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.
“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.
Global studies have indicated strong patient preference for subcutaneous administration.
According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:
Studies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.
In the IMscin001 study presented at ESMO 2023:
Credit: AI generated image
Even as Polycystic Ovary Syndrome (PCOS) got rebranded as Polyendocrine Metabolic Ovarian Syndrome (PMOS), it signals a major shift in how doctors understand and treat one of the most common hormonal conditions affecting women, said health experts today.
Speaking to HealthandMe, the experts noted that from the earlier narrowed focus on ovarian cysts, the transition toward PMOS will better capture the condition’s complex metabolic and endocrine nature.
Dr. Isha Kriplani, Consultant – Obstetrics and Gynecology at Paras Health, said the renaming marks “the beginning of a new era in women's gynecological health.”
Also read: PCOS Is Now PMOS: What The Name Change Means For Millions Of Women
The new name aims to explain the condition more accurately and comprehensively.
Polyendocrine means it affects multiple hormones in the body.
Metabolic refers to issues linked to weight, insulin, blood sugar, and heart health.
Ovarian highlights its impact on ovulation and reproductive health.
Syndrome refers to a group of symptoms occurring together.
In simple terms, PMOS is a hormonal and metabolic condition that can affect periods, fertility, skin, mood, weight, and long-term health.
Dr. Isha stated that the term PMOS acknowledges that the disorder is not solely linked to hormonal imbalance or ovarian dysfunction, but also deeply connected to metabolic health. She explained that many women experience symptoms such as weight gain, skin issues, fatigue, insulin resistance, and hormonal disturbances without necessarily showing ovarian cysts on ultrasonography.
“Rebranding Polycystic Ovary Syndrome (PCOS) into Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the beginning of a new era in women's gynecological health. This is because renaming helps us understand that the complex interplay of this disease is not only about imbalanced hormones but also metabolism,” she told HealthandMe.
Dr. Isha added that the shift could help broaden diagnosis and encourage early intervention to prevent long-term complications such as type 2 diabetes and hypertension. She noted that the new terminology also provides women with a more accurate understanding of the syndrome and encourages treatment strategies focused on addressing the root metabolic causes.
Dr. Raina Chawla, Associate Director – Gynecology at Sarvodaya Hospital, told HealthandMe the transition from PCOS to PMOS corrects what she described as one of medicine’s “most persistent misnomers.”
She explained that for years, the term PCOS led many patients to believe the condition was purely ovarian in nature, often resulting in confusion and delays in diagnosis. According to Dr. Raina, the so-called “cysts” seen in PCOS are actually immature follicles that develop as a consequence of the disorder rather than being its primary cause.
Also read: PCOD vs PCOS vs PMOS: Why The Condition’s Name Has Changed Over Time
“The shift from PCOS to Reproductive Metabolic Syndrome (PMOS) is an important move toward correcting one of medicine’s most persistent misnomers,” Dr. Raina said.
She further emphasized that the newer terminology places appropriate attention on insulin resistance and androgen excess, helping doctors and patients approach the disorder as a systemic endocrine and metabolic condition rather than a localized ovarian issue.
Experts believe the change in terminology could also reduce stigma and improve awareness about the wide-ranging symptoms associated with the syndrome, while encouraging a more holistic treatment approach that includes lifestyle modifications, metabolic screening, and long-term preventive care.
© 2024 Bennett, Coleman & Company Limited